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Introduction: The efficacy of rituximab (RTX) in Systemic Lupus Erythematosus (SLE) is 
debated. We describe the outcomes of a European SLE cohort treated with RTX, with 
emphasis on its role as a maintenance agent. 
 
Methods: All patients with SLE receiving RTX as induction across four centres were included, 
follow-up post RTX was collected including the subgroup treated with RTX as maintenance 
treatment (RMT). Disease flares during the follow-up were defined as an increase in disease 
activity and immunosuppressive drugs. 
 
Results: Of 147 patients, at 6 months 27% experienced treatment failure (TF); in a 
multivariate analysis, a low number of previous immunosuppressive therapies (p=0.034) and 
low C4 levels (p=0.008) reduced the risk of TF. Eighty patients received RMT over a median 
of 24.5 months during which 85 relapses, mainly musculoskeletal, were recorded (1.06 per 
patient); at the last RTX course, 84% of the patients were in remission. 28/80 (35%) patients 
never flared during the RMT with low damage accrual; active articular disease at the time of 
the first RTX course was associated with risk of flare during RMT (p=0.010). After RMT, 
relapse free survival was similar to patients receiving a single-RTX course (p=0.72). 
 
Conclusions:  
RMT is a potential treatment option in difficult to treat patients. Relapses occur during RMT 
and are more likely in those with active articular disease at the time of the first RTX. Relapse 




Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterised by clinical 
variability and complex pathogenesis(1, 2). B-cell depleting strategies have received 
continued attention in SLE(1) and, although rituximab (RTX) has proven effective in other 
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randomised controlled trials (RCTs) exploring RTX in SLE(4, 5) have failed to meet their 
primary end-points.  
 
Sustained remission is the goal for disease management although infrequently achieved(6); 
improving the management of the maintenance phase of SLE is therefore an unmet need(7). 
Newer therapeutic options are needed and RTX is frequently employed in relapsing and 
refractory cases(8), its use is supported by retrospective and prospective non-randomised 
studies(1). 
 
The discrepancy between the RCTs results and those observed in real-life settings suggests 
that solid predictors of response to RTX must be identified in order to better tailor the 
treatment strategies. Clinical predictors of response to RTX in SLE have been investigated, 
with heterogeneous results across different cohorts(9). Having severe disease, lack of 
haematological involvement or previous treatment with high dose steroids were associated 
with a good response in 116 patients(10); younger age and achievement of B-cell depletion 
six weeks after treatment with RTX were other favourable characteristics in a different 
population of 117 patients(11). Among biomarkers, the proportion of plasmablasts 6 
months after RTX(11) and a single nucleotide polymorphism in the IL2/IL21 area have been 
associated with response(12); the former replicated in two different cohorts while the 
latter, although with a strong biological rationale(13), so far replicated only in a cohort of 
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Importantly, in RTX treated patients time to relapse is highly variable(15, 16); relapses are 
associated to risk of damage accrual and therefore attention should be focused on flare 
prevention aiming at the right balance between immunosuppressive drug dosing, risk of 
toxicity and disease activity. RTX has a proven role as a maintenance agent in other 
autoimmune diseases(3) while in SLE, there is little published experience of repeat dose 
RTX(17-21). Of note the cohorts were small, the number of cycles low and the indications 
for repeating the treatment heterogeneous while no study has so far explored its use as 
maintenance treatment with the aim of relapse prevention. 
 
In this study, we explore the efficacy and safety of RTX in a cohort of 147 patients with SLE 
with an emphasis on the subgroup of 80 patients re-treated with the drug as a maintenance 
agent in order to prevent relapses; prognostic factors associated with the response to RTX 
were also investigated. 
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Treatment protocol The patients were either treated with a “Single-RTX course” or with  “RTX maintenance treatment” (RMT). “Single-RTX course” was any RTX dosing performed within a single month, such as 1 g or 375 mg/m2 given two weeks apart or for four consecutive weeks respectively. Patients receiving at least three “Single-RTX courses” with the aim of relapse prevention and with an interval of 4 to 8 months between consecutive treatments were classified as receiving RMT. Patients receiving RTX courses that did not meet this definition were censored at time of re-treatment. Treatment associated to RTX administration and data collected during the follow-up are reported in the 
supplementary methods. This a retrospective study, therefore no clear indications for treatment selection as well as RTX schedule within the RMT group was provided and it was result of the single physician experience and choice.  
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modulating therapy dose of 0-25%.  Any other case was defined as treatment failure (TF).  Disease flares during RMT or after the first-last RTX course were defined as an increase in at least two of three parameters among PA, ECLAM, immunosuppressive-corticosteroids number/dose.   Patients were stratified in four groups according to disease severity: Mild, Moderate, Severe and Drug Sparing. The first three groups were defined according to the British Society of Rheumatology guidelines(8); the group “Drug Sparing” included patients with Mild or Moderate disease to whom RTX was administered with the aim of sparing an on-going immunosuppressive agent or avoiding an alternative immune suppressors contraindicated for the patient.  Late onset neutropenia (LON) definition and damage assessment methods are reported in the supplementary methods.  










This article is protected by copyright. All rights reserved. 
Methods for comparison of changes in variables and proportions of patients as well as for Univariate and multiple logistic regression are reported in the supplementary 
methods. 
 Time to relapse was assessed by the Kaplan-Meier survival analysis, and if comparisons between populations were required, the log-rank test was used. Two sided p-values <0.05, were considered statistically significant. 
 
RESULTS 










This article is protected by copyright. All rights reserved. 
At the multivariate analysis adjusted for confounding factors (other immunosuppressive drugs administered and prednisolone dose), the characteristics associated with the risk of experiencing TF were higher C4 levels (OR 1.76 (1.15-2.7), p=0.008) and the number of previous immunosuppressive agents (OR 7.77 (1.65-36.6), p=0.034) (Table S1).  
RTX Maintenance Treatment (RMT) 80/147 (54%) patients were treated with RMT; their characteristics are summarised in 
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 After six months ECLAM declined to a mean of 1.86 (95%CI 1.52-2.19) (p<0.0001) with a trend towards further reduction/stabilisation during maintenance treatment (figure 
1); at the six month assessment 30/80 patients (38%) were in CR and this proportion increased to 40–51 and 48% respectively at the 12, 18 and 24 month assessment. The proportion of patients not taking corticosteroids increased from 14% to 41% while the mean dose of prednisolone dropped from 11 mg/day (95%CI 8.9-13) at RTX initiation to 3.8 (95%CI 1.1-6.4) by the 6th administration; a trend towards a reduction of the proportion of patients receiving other immunosuppressive drugs was also observed 
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Outcome after the last RTX infusion Of the 67 patients that received a single-RTX course, 54 (80%) experienced a CR or PR at the sixth month assessment and were therefore followed for post therapy flare; the median follow-up after the sixth month assessment was 7.3 months (IQR 3.46-9.78). Eighteen flares (33%) were observed (51.5 flares per 100-patient year); the mean ECLAM score for the flaring patients was 2.94 (95%CI 1.97-3.91); the sites showing active disease and the flare management are shown in Table S4.   Of the 80 patients receiving RMT, post-treatment follow-up was available in 57 (71%); the median follow-up after the last RTX was 13 months (IQR 4-22). Thirty (53%) flares were observed (38 flares per 100-patient year); the mean ECLAM score for flaring patients was 3.09 (95% CI 2.6-3.58); the sites showing active disease and flare management are shown in Table S4.  
 The rate of flares involving major organs during RMT was 38%, this increased to 67% when RMT was withdrawn (p=0.01); in particular, the flare rate per 100 patient-years involving neurological, pulmonary and haematological systems after RMT increased compared to the one observed during RMT while the renal ones remained stable (figure 
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Sustained responders Among the 80 patients of the RMT cohort, 28 (35%) did not experience any flare during the maintenance period (“Sustained responders”). When comparing the group of the “Sustained responders” to those with at least one flare, the presence of active articular disease at the time of the first RTX administration was at multivariate analysis associated with the risk of flare [OR 3.55 (95%CI 1.34-9.37) p=0.010] (Table 2) even after adjusting the analyses for the disease severity considered as a potential a priori confounder [OR 3.38 (95%CI 1.25-9.11) p=0.016].  Post-RMT follow-up was available for 21/28 of the Sustained responders (75%); the median follow-up was 17.5 months (IQR 5.3-23.8). 10/21 patients (48%) flared (27 flares per 100-patient year); the mean ECLAM score for flaring patients was 2.45 (95%CI 1.64–3.27); sites showing active disease at the time of the flare were joints in 5 (50%), haematological in 4 (40%), renal and CNS in 2 (20%) and skin in 1 (10%). Flares were managed by increasing the prednisolone dose in 4 (40%), starting a new immunosuppressive drug in 4 (40%), increasing the dose of an on-going immunosuppressive drug in 1 (10%) and in three patients (30%) no treatment changes were recorded.     
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cumulative number and the proportions of the different SAEs did not differ between the patients treated with RMT and those treated with a single-RTX course (data not shown).  Sixteen episodes of LON were recorded during the 452 RTX administrations (4%) in 9/80 patients (11%) with four patients experiencing two or more episodes; ten episodes were of grade II, 4 of grade III and 2 of grade IV. In two patients the first episode of LON happened after the first RTX administration while in seven after one of the following cycles; the median time from the last RTX administration and the LON detection has been of 8 months (IQR 5-11). Of the two patients experiencing grade IV LON, one died of neutropenic sepsis and one was admitted for clinical monitoring without experiencing any infection or requiring any specific therapy.  Eleven patients died during follow-up, 2/67 (3%) in the group that did not receive RMT and nine (9/80, 11.3%) in the RMT group; in the latter group seven died during RMT and two after (respectively 19 and 35 months after the last RTX infusion).  Details regarding the cause of death are reported in Table S7.  
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The increase in SLICC per patient per year pre-RTX administration was 0.21 while during the RMT it was 0.23; in the “Sustained responders” subgroup the increase in the SLICC per patient per year was 0.17.  
Laboratory parameters During RMT C3 and C4 levels remained stable if they were normal at the time of the first RTX administration (figure 4); in the subgroup of patients with reduced levels the values increased to normal and then stabilised (figure S1). IgG levels remained stable during the RMT whereas a trend towards reduction for IgM was noted (figure 4). Anti-DNA levels assessed with ELISA decreased after the first RTX to fall within the normal range and to remain stable during the RMT (figure S2). CD19+ B-cells were undetectable in 76% of the patients at the time of the second RTX and tended to remain the same during follow-up (figure S3).   
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Despite the challenges deriving from the management of active SLE, the maintenance phase plays a critical role in the long-term outcome, influencing damage accrual(7). In 
RTX treated patients time to relapse is highly variable(15, 16) and a RTX based maintenance 
treatment at fixed intervals may be attractive. 
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involvement at the time of the first RTX were less likely to experience relapses during RMT. At the time of drug withdrawal, relapse free survival remains apparently comparable to the one of patients treated with a single-RTX course. A RMT regimen might be considered for patients with severe disease-related complications, for whom waiting for the relapse in order to treat on demand may be risky, and when first-line immunosuppressive options are exhausted.  
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TABLES AND FIGURES 
 
Table 1. Main characteristics of the 147 SLE patients treated with RTX.. 




Age (years) 45 (42-48)  42 (39-46) 44 (41-46) 
Gender - Female 71 (90%) 63 (94%) 134 (91%) 
Ethnicity - Caucasian 74 (93%) 62 (93%) 136 (93%) 
Prior disease duration (months) 154 (100-208)  114 (87-141)  133 (104-161) 
RTX given at the time of diagnoses  3 (4%) 4 (6%) 7 (5%) 
Organ manifestations at first RTX 
administration 
   Musculoskeletal 52 (65%) 35 (53%) 87 (60%) Skin 49 (61%) 31 (46%) 80 (54%) Haematological 26 (33%) 37 (55%) 63 (43%) Pulmonary 18 (23%) 6 (9%) 24 (16%) Renal 15 (19%) 37 (55%) 52 (36%) Neurological 14 (18%) 8 (12%) 22 (15%) 
Previous therapies    Mycophenolate mofetil 67 (84%) 42 (63%) 109 (74%) Hydroxychloroquine 61 (76%) 38 (57%) 99 (67%) Azathioprine 41 (51%) 26 (39%) 67 (46%) Methotrexate 26 (33%) 13 (19%) 39 (27%) Cyclophosphamide 24 (30%) 21 (31%) 45 (31%) Rituximab  14 (18%) 12 (18%) 26 (18%) Calcineurin inhibitor 11 (14%) 24 (36%) 35 (24%) Anti-TNF therapy 6 (8%) 3 (4%) 9 (6%) Plasma exchange 4 (5%) 2 (3%) 6 (4%) IV immunoglobulins 4 (5%) 6 (9%) 10 (7%) Other  10 (13%) 9 (13%) 19 (13%) 
Previous immunosuppressive 
therapies per patient £ 
4.3 (4-4.7) 3.9 (3.5-4.4) 4.1 (3.9-4.4) 
Severity of Disease    Mild 20 (25%) 4 (6%) 24 (16%) Moderate 6 (7%) 17 (25%) 23 (16%) Severe 40 (50%) 34 (51%) 74 (50%) Drug Sparing 14 (18%) 12 (18%) 26 (18%) 
Laboratory Data     Anti-DNA level (IU/mL) 67.2 (31.9-104.5) 75.4 (39-111.5)  71 (46-96)  C3 (g/L) 1.1 (1.02-1.21)  0.85 (0.75-94)  1 (0.92-1.07)   C4 (g/L) 0.2 (0.18-0.24)  0.15 (0.12-0.18)  0.18 (0.16-0.2)  
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Table 2. Clinical characteristics and their association with the risk of experiencing 
at least one flare during the RMT at univariate and multivariate analyses  
° Odds ratio expressed for 0.1 increase  $ Odds ratio expressed for unit increase of the independent variable 
 
 
 Univariate Multivariate 
Variable Odds ratio p Odds ratio p Gender  Female (reference)  Male 
  1  4.8 (0.57-40.5) 
0.150 - - 
Number of immunosuppressive drugs before RTX  0-2 (reference)  3-4  >4 
  1  1.51 (0.51-4.46)  0.93 (0.22-4) 
0.650 - -
Physician Assessment at RTX  0  1  2 
  1  2.81 (0.39-20.4)  3.08 (0.47-20.23) 
0.501 - - 
Clinical manifestations at RTX     Systemic 2.00 (0.77-5.16) 0.150 - -
Articular  3.55 (1.34-9.37) 0.011 3.55 (1.34-9.37) 0.011 
Skin  2.67(1.04-6.87) 0.042 - - Muscle  0.51 (0.07-3.83) 0.512 - -Pulmonary 1.65 (0.53-5.18) 0.390 - -CNS 2.18 (0.55-8.58) 0.264 - - Renal 0.56 (0.18-1.754) 0.316 - - Hematologic  0.64 (0.24-1.70) 0.373 - -ECLAM score at RTX $ 1.02 (0.80-1.29) 0.887 - - 
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Figure 1.  Changes of the ECLAM score, prednisolone and immunosuppressive 
treatment in the 80 SLE patients who received RTX Maintenance Treatment 
(RMT) for relapse prevention. Panel A. Data are shown as mean with whiskers representing the 95% confidence interval. The grey area includes the part of the follow-up after the first RTX administration. The * indicates a reduction of ECLAM score statistically significant compared to baseline Panel B. Bars show the proportion of patients either receiving (light grey) or not receiving (dark grey) other immunosuppressive drugs at the moment of the first RTX administration and during the RMT; the line represents the changes in the mean (95%CI) prednisolone (PDN) dose. The star highlights a significant difference compared to baseline (p<0.05).   
Figure 2.  Major organ involvement at the time of flare during and after RTX 
Maintenance Treatment (RMT) 
  
Figure 3.  Relapse free survival of two cohorts of patients with SLE after the last 
RTX administration. The red curve is showing the relapse free survival in a group of patients treated with a single-RTX course, the green curve the relapse free survival in cohort treated with RTX Maintenance Treatment (RMT) after the last RTX course. Panel A refers to the overall population, Panel B included as event only the non-musculoskeletal flares.   
Figure 4.  Complement and immunoglobulin levels during follow-up in a cohort of 
80 SLE patients receiving RTX Maintenance Treatment (RMT) with the aim of 
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